Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-20

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 4, open-label, single-dose, parallel-group, multicenter, safety study of cefazolin (1 g or 2 g) in pediatric subjects between 10 and 17 years of age (inclusive) scheduled for surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pediatric Cefazolin PK Study

NCT01904357

Infections

COMPLETED PHASE1

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

NCT05205486

Infections

COMPLETED PHASE1

Cefazolin PK Study 3g vs 2g

NCT05309304

Healthy

COMPLETED PHASE1

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

NCT01121354

Infection

COMPLETED PHASE1

An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates

NCT00850122

Sepsis Prematurity

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 110 subjects will be enrolled and assigned to 1 of the 2 dose groups in a 1:1 ratio (55 subjects in each group). Subjects with a weight of at least 25 kg but less than 60 kg will receive a single IV dose of 1 g cefazolin. Subjects with a weight of at least 60 kg will receive a single IV dose of 2 g cefazolin. Dose groups will not be balanced by age or gender. Additional subjects may be enrolled if necessary to ensure at least 50 evaluable subjects with complete safety data per dose group complete the study.

In a subset of approximately 40 subjects, 4 PK samples will be obtained to determine the cefazolin plasma concentrations in this population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Approximately 110 subjects will be enrolled and assigned to 1 of the 2 dose groups in a 1:1 ratio (55 subjects in each group). Subjects with a weight of at least 25 kg but less than 60 kg will receive a single IV dose of 1 g cefazolin. Subjects with a weight of at least 60 kg will receive a single IV dose of 2 g cefazolin. Dose groups will not be balanced by age or gender.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

n/a, this is an open label study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cefazolin 1 g Infusion

Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.

Group Type ACTIVE_COMPARATOR

Cefazolin 1 g Infusion

Intervention Type DRUG

1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg

Cefazolin 2 g Infusion

Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.

Group Type ACTIVE_COMPARATOR

Cefazolin 2 g Infusion

Intervention Type DRUG

2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cefazolin 1 g Infusion

1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg

Intervention Type DRUG

Cefazolin 2 g Infusion

2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject is between the ages of 10 and 17 years (inclusive) at the time of giving informed consent.
2. The subject is scheduled for surgery that will last less than 3 hours.
3. The subject and the subject's legally authorized representative voluntarily agree that the subject will participate in this study. In accordance with applicable laws, regulations, and institutional review board requirements, the subject signs or orally agrees to an age-appropriate assent and the subject's legally authorized representative signs both an institutional review board approved informed consent form and Health Insurance Portability and Accountability Act authorization prior to the performance of any screening procedures.
4. For subjects who agree to participate in the PK subgroup additional consent will be obtained.
5. The subject weighs (on Day 1) ≥25 kg but \<60 kg for inclusion in 1 g dose group.
6. The subject weighs (on Day 1) ≥60 kg for inclusion in 2 g dose group.
7. The subject has been scheduled for any type of surgery requiring single dose perioperative cefazolin prophylaxis.

Exclusion Criteria

1. Female subjects who are pregnant or lactating/breastfeeding.
2. Female subjects of childbearing potential who are sexually active and who are not willing to use an effective method of birth control during the study period, eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or have a partner with a vasectomy.
3. The subject has impaired renal function based on the revised Schwartz formula.
4. The subject has a known allergy or hypersensitivity to β lactam/cephalosporin antibiotics, penicillins, corn products, or dextrose containing products or solutions, or any of the other ingredients of Cefazolin for Injection United States Pharmacopeia (USP) and Dextrose Injection USP in DUPLEX.
5. The subject has abnormal vital signs or an abnormal electrocardiograph (ECG) considered by the investigator to be clinically significant.
6. The subject has a result of any laboratory test (or repeat test, if done), obtained as standard of care, that is outside the normal limit of the site's laboratory reference range AND is considered by the investigator to be clinically significant.
7. The subject has a known history of human immunodeficiency virus, hepatitis B, or hepatitis C infection.
8. The subject has a history of alcohol or drug abuse.
9. The subject has received any other investigational drug/device within 30 days prior to the study drug administration.
10. The subject has a history of or is currently smoking or using nicotine-containing substances or electronic cigarettes as determined by medical history or subject's verbal report.

Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No